Fulcrum Therapeutics, Inc. (FULC) Earnings Call Transcripts

Fulcrum Therapeutics, Inc.'s Latest Earnings Call - Q1 FY2026

Fulcrum Therapeutics reported its Q1 2026 earnings, highlighting significant progress with its lead candidate, pociredir, for sickle cell disease. The company showcased positive clinical data from the Phase Ib PIONEER trial, demonstrating a substantial increase in fetal hemoglobin levels from 7.1% to 19.3% over 12 weeks. Fulcrum ended the quarter with a net loss of $22.2 million, compared to $20.4 million in Q1 2025, and a cash position of $333.3 million, providing runway into 2029. Management did not provide specific revenue or earnings guidance but indicated plans to initiate a registration-enabling trial in H2 2026 pending FDA feedback.

Reported metrics

Guidance from management

Fulcrum plans to initiate a registration-enabling trial for pociredir in the second half of 2026, pending FDA feedback. No specific revenue or earnings guidance was provided.

What management said

That's great. Thanks so much, Alan. So Fulcrum has reached an important inflection point with the positive clinical data from our PIONEER trial, reinforcing our conviction in pociredir's potential in sickle cell disease. We are focused on the next stage of development and look forward to providing an update on our plans following our upcoming end-of-phase meeting with the FDA. And with a strong balance sheet and a ...

I think you captured it very well, Alex. It's the severity of the disease and the manifestations experienced by these patients coupled with the really high unmet need in terms of available therapies for the patients. And I think on a daily basis, we continue to be reminded of that.

What analysts pressed on

Analysts expressed interest in the competitive landscape and regulatory dynamics, particularly regarding the potential for combination therapies and the role of fetal hemoglobin as a surrogate endpoint for accelerated approval.

Main topics on the call

• PIONEER Trial Results — The PIONEER trial showed that pociredir increased fetal hemoglobin levels from 7.1% to 19.3% at 12 weeks, with 7 out of 12 patients experiencing no vaso-occlusive crises. Management stated, 'pociredir has continued to be...
• Financial Position — Fulcrum reported a net loss of $22.2 million for Q1 2026, with cash, cash equivalents, and marketable securities totaling $333.3 million. The company expects this to fund operations into 2029.
• Regulatory Pathway — Fulcrum plans to initiate a registration-enabling trial for pociredir in H2 2026, pending FDA feedback. The company is focused on aligning with regulators on the optimal strategy for demonstrating clinical benefit.
• Management Changes — CFO Alan Musso announced his retirement, with a transition plan in place. Josh Lehrer joined the Board of Directors, bringing experience in sickle cell disease therapies.

Read the full Fulcrum Therapeutics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 46 Fulcrum Therapeutics, Inc. earnings call transcripts on record, spanning March 5, 2020 to August 17, 2026. Based on this history, Fulcrum Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

FULC

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

46

First call

March 5, 2020

Most recent

August 17, 2026

Reporting cadence

quarterly